Accelerate Diagnostics Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics or view top-rated stocks.

Wall Street analysts have given Accelerate Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Accelerate Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Accelerate Diagnostics.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) released its earnings results on Wednesday, August, 4th. The medical research company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.03.
View Accelerate Diagnostics' earnings history.

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXDX shares have decreased by 44.0% and is now trading at $5.94.
View which stocks have been most impacted by COVID-19.

2 analysts have issued 12-month target prices for Accelerate Diagnostics' stock. Their forecasts range from $9.00 to $9.00. On average, they expect Accelerate Diagnostics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 51.5% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Accelerate Diagnostics include Singular Genomics Systems (OMIC), Rapid Micro Biosystems (RPID), Akoya Biosciences (AKYA), Fluidigm (FLDM), Codex DNA (DNAY), Harvard Bioscience (HBIO), EyePoint Pharmaceuticals (EYPT), Talis Biomedical (TLIS), Precipio (PRPO), Astrotech (ASTC), SeqLL (SQL), Scientific Industries (SCND), Pressure BioSciences (PBIO), BioForce Nanosciences (BFNH) and PositiveID (PSID).
View all of AXDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.81%), Birchview Capital LP (3.66%), Vanguard Group Inc. (2.78%), AXA S.A. (2.68%), Chicago Capital LLC (2.47%) and Cannell Peter B & Co. Inc. (1.79%). Company insiders that own Accelerate Diagnostics stock include Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including Rafferty Asset Management LLC, Chicago Capital LLC, BlackRock Inc., Bank of America Corp DE, Millennium Management LLC, Bank of New York Mellon Corp, Wolverine Trading LLC, and Susquehanna International Group LLP. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Jack Phillips, Ron Price, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or view top insider-selling stocks.

AXDX stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Nuveen Asset Management LLC, Baird Financial Group Inc., Parametric Portfolio Associates LLC, Geode Capital Management LLC, Group One Trading L.P., and Charles Schwab Investment Management Inc.. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or or view top insider-buying stocks.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXDX stock can currently be purchased for approximately $5.94.

Accelerate Diagnostics has a market capitalization of $365.30 million and generates $11.16 million in revenue each year. The medical research company earns $-78,210,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

Accelerate Diagnostics employs 224 workers across the globe.

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Accelerate Diagnostics is headquartered at 3950 South Country Club Suite 470, Tucson AZ, 85714.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at (520) 365-3100 or via email at [email protected]